| Collaborations |
|
Johnson & Johnson
Cephalosporin which is currently in pre-clinical stages - and will target Staphylococcal infections, Enterococcal infections, and Streptococcus pneumoniae infections.
|
|
Daiichi Pharmaceutical Co., Ltd.
A 3 year collaboration entered into November 1995. The focus is on compounds that would overcome the efflux pump mechanism of bacterial resistance, to be used in combination with antibiotics targeting pseudomonas.
|